Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment

NCT00134953 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00134953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00134953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2003
Completion date
May 31, 2004
Enrollment
24
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive symptoms